

# Summary of Product Characteristics

## 1 NAME OF THE MEDICINAL PRODUCT

Dexlansoprazole Takeda 60mg modified-release capsules, hard

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains 60 mg of dexlansoprazole.

### Excipients with known effect:

Each 60 mg modified-release capsule contains 76 mg of sucrose.

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Modified-release capsule, hard

Each 60mg capsule (size 2) is opaque with a blue cap and body with 'TAP' imprinted on the cap and '60' on the body.

## 4 CLINICAL PARTICULARS

### 4.1 Therapeutic Indications

Dexlansoprazole Takeda is indicated in adults for the following:

- Treatment of erosive reflux oesophagitis
- Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn
- Short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD)

### 4.2 Posology and method of administration

#### Posology

-Treatment of erosive reflux oesophagitis

The recommended dose is 60 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.

- Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn.

The recommended dose is 30 mg once daily for up to 6 months in patients where prolonged acid suppression is needed.

-Symptomatic non-erosive gastro-oesophageal reflux disease (GORD)

The recommended dose is 30 mg once daily for up to 4 weeks.

#### Special populations

##### *Elderly*

Due to reduced clearance of dexlansoprazole in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications (see section 5.2).

### *Renal impairment*

No dosage adjustment is necessary for patients with renal impairment (see section 5.2).

### *Hepatic impairment*

No dosage adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment should be kept under regular supervision and a maximum daily dose of 30 mg should be considered. No studies have been conducted in patients with severe hepatic impairment (see sections 4.4 and 5.2), the use of dexlansoprazole is not recommended for these patients.

### *Paediatric population*

The safety and efficacy of Dexlansoprazole Takeda in children and adolescents under 18 years of age have not been established. No data are available.

### Method of administration

Oral use.

Capsules should be swallowed whole with liquid. They can be taken with or without food (see section 5.2).

Capsules may also be opened and granules mixed with one tablespoon apple sauce for administration. After preparing the mixture, the medicinal product should be administered immediately.

Granules should not be chewed.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Dexlansoprazole should not be administered with atazanavir or nelfinavir (see section 4.5).

## **4.4 Special warnings and precautions for use**

The possibility of malignant gastric tumour should be excluded when using Dexlansoprazole Takeda because dexlansoprazole can mask the symptoms and delay the diagnosis.

Dexlansoprazole should be used with caution in patients with moderate hepatic dysfunction. Dexlansoprazole is not recommended for patients with severe hepatic impairment (see sections 4.2 and 5.2).

Decreased gastric acidity due to any means, including proton pump inhibitors (PPIs) such as dexlansoprazole, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with PPIs may lead to slightly increased risk of gastrointestinal infections such as *Salmonella*, *Campylobacter* and *Clostridium difficile*.

Because of limited safety data for patients on treatment for longer than 1 year, regular review of the treatment and a thorough risk/benefit assessment should regularly be performed in these patients.

Severe hypomagnesaemia has been reported in patients treated with PPIs like dexlansoprazole for at least three months, in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Very rarely cases of colitis have been reported in patients taking lansoprazole. Similar effects could be expected with dexlansoprazole. Therefore, in the case of severe and/or persistent diarrhoea, discontinuation of therapy should be considered.

Proton pump inhibitors, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10–40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.

When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high dose methotrexate administration a temporary withdrawal of dexlansoprazole may need to be considered.

As Dexlansoprazole Takeda contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

Interaction studies have only been performed in adults.

##### Effects of other drugs on dexlansoprazole

CYP2C19 and CYP3A4 have been shown to be involved in the metabolism of dexlansoprazole.

##### *Drugs which inhibit CYP2C19*

Inhibitors of CYP2C19 (such as fluvoxamine) would likely increase the systemic exposure of dexlansoprazole.

##### *Drugs which induces CYP2C19 and CYP3A4*

Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin, and St John's wort (*Hypericum perforatum*) may reduce the plasma concentrations of dexlansoprazole.

##### *Others*

##### *Sucralfate/Antacids*

Sucralfate/Antacids may decrease the bioavailability of dexlansoprazole. Therefore dexlansoprazole should be taken at least 1 hour after taking these drugs.

##### Effects of dexlansoprazole on other drugs

##### *Medicinal products with pH dependent absorption*

Dexlansoprazole may interfere with the absorption of drugs where gastric pH is critical to bioavailability.

##### *Atazanavir and nelfinavir*

A study has shown that co-administration of lansoprazole (60 mg once daily) with atazanavir 400 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 90% decrease in AUC and  $C_{max}$ ).

Similar effect would be expected with dexlansoprazole. Dexlansoprazole should not be co-administered with atazanavir (see section 4.3).

A study has shown that co-administration of omeprazole (40 mg once daily) with nelfinavir 1250 mg twice daily to healthy volunteers resulted in a significant reduction in nelfinavir exposure (approximately 36% and 37% decrease in AUC and  $C_{max}$ , respectively). Although interaction studies with dexlansoprazole have not been conducted, reduction of AUC and  $C_{max}$  of nelfinavir may be expected with dexlansoprazole. Therefore, dexlansoprazole should not be co-

administered with nelfinavir (see section 4.3).

#### Ketoconazole, itraconazole and erlotinib

The absorption of ketoconazole, itraconazole and erlotinib from the gastrointestinal tract is enhanced by the presence of gastric acid. Administration of dexlansoprazole may result in sub-therapeutic concentrations of ketoconazole, itraconazole and erlotinib, and the combination should be avoided.

#### Digoxin

Co-administration of dexlansoprazole and digoxin may lead to increased digoxin plasma levels. The plasma levels of digoxin should therefore be monitored and the dose of digoxin adjusted if necessary when initiating and ending dexlansoprazole treatment.

#### *Medicinal products metabolised by P450 enzymes*

In vitro studies have shown that Dexlansoprazole Takeda is not likely to inhibit CYP isoforms 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 or 3A4. As such, no clinically relevant interactions with drugs metabolised by these CYP enzymes would be expected. Furthermore, *in vivo* studies showed that Dexlansoprazole Takeda did not have an impact on the pharmacokinetics of co-administered phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate). The subjects' CYP1A2 genotypes in the drug-drug interaction study with theophylline were not determined. Although *in vitro* studies demonstrated that Dexlansoprazole Takeda has the potential to inhibit CYP2C19, an *in vivo* drug-drug interaction study in mainly CYP2C19 extensive and intermediate metabolisers has shown that Dexlansoprazole Takeda does not affect the pharmacokinetics of diazepam (CYP2C19 substrate).

#### Tacrolimus

Co-administration of dexlansoprazole may increase the plasma concentrations of tacrolimus (a CYP3A and P-glycoprotein [P-gp] substrate), especially in transplant patients who are intermediate or poor metabolisers of CYP2C19. Monitoring of tacrolimus plasma concentrations is advised when concomitant treatment with dexlansoprazole is initiated or ended.

#### Warfarin

In a study, co-administration of Dexlansoprazole Takeda and warfarin did not result in any significant differences in the pharmacokinetics of warfarin or International Normalised Ratio (INR) compared to administration of warfarin with placebo. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time.

#### Clopidogrel

A study has shown that concomitant administration of dexlansoprazole (60 mg once daily) and clopidogrel 75 mg to healthy volunteers resulted in a reduction in the exposure to the active metabolite of clopidogrel (approximately 9% decrease in AUC and 27% decrease in  $C_{max}$ ). Co-administration of dexlansoprazole had no clinically meaningful effect on pharmacodynamics of clopidogrel. No dose adjustment of clopidogrel is necessary when administered with an approved dose of Dexlansoprazole Takeda.

#### *Methotrexate*

Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of high-dose methotrexate with PPIs have been conducted.

#### *Medicinal products transported by P-glycoprotein*

Lansoprazole has been observed to inhibit the transport protein, P-gp *in vitro*. Similar effects could be expected with dexlansoprazole. The clinical relevance of this is unknown.

### Others

No clinically significant interactions of dexlansoprazole with non-steroidal anti-inflammatory drugs have been demonstrated, although no formal interactions studies have been performed.

## 4.6 Fertility, pregnancy and lactation

### Pregnancy

There are no or limited amount of data from the use of dexlansoprazole in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of Dexlansoprazole Takeda during pregnancy.

### Breastfeeding

It is not known whether dexlansoprazole is excreted in human breast milk. Animal studies have shown excretion of lansoprazole in milk.

A risk to the newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

### Fertility

There was no evidence of impaired fertility following the administration of lansoprazole in animal studies (see section 5.3). Similar results could be expected with dexlansoprazole.

## 4.7 Effects on ability to drive and use machines

Adverse drug reactions such as dizziness, vertigo, visual disturbances and somnolence may occur (see section 4.8). Under these conditions the ability to react may be decreased.

## 4.8 Undesirable effects

### Summary of the safety profile

Dexlansoprazole Takeda at doses of 30, 60, or 90 mg has been evaluated for safety in clinical studies in patients treated for up to 1 year. In these clinical studies, adverse reactions associated with treatment with Dexlansoprazole Takeda were mostly mild or moderate, with an overall incidence similar to placebo and lansoprazole. The most commonly reported adverse reactions were diarrhoea, abdominal pain, headache, nausea, abdominal discomfort, flatulence and constipation. The incidence of these adverse reactions was not affected by gender, age, or race.

### Tabulated list of adverse reactions

Adverse reactions reported for Dexlansoprazole Takeda (30 mg, 60 mg or 90 mg) in clinical studies and post-marketing experience are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1,000$  to  $< 1/100$ ); rare ( $\geq 1/10,000$  to  $< 1/1,000$ ); very rare ( $< 1/10,000$ ); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

System organ class	Common	Uncommon	Rare	Not known
Blood and lymphatic system				Autoimmune haemolytic anaemia <sup>1,2</sup>

disorders				Idiopathic thrombocytopenic purpura <sup>2</sup>
Immune system disorders				Anaphylactic reaction <sup>2</sup> Hypersensitivity <sup>1,2</sup> Stevens-Johnson syndrome <sup>2</sup> Toxic epidermal necrolysis <sup>2</sup> Anaphylactic shock <sup>2</sup>
Metabolism and nutrition disorders				Hypomagnesaemia <sup>2</sup> [see Special warnings and precautions for use (4.4)]
Musculoskeletal and connective tissue disorders		Fracture of the hip, wrist or spine (see section 4.4)		
Psychiatric disorders		Insomnia Depression	Auditory hallucinations	
Nervous system disorders	Headache	Dizziness Altered taste	Convulsion Paraesthesia	
Eye disorders			Visual disturbance	Blurred vision <sup>2</sup>
Ear and labyrinth disorders			Vertigo	Deafness <sup>2</sup>
Vascular disorders		Hypertension Hot flushes		
Respiratory, thoracic and mediastinal disorders		Cough		
Gastrointestinal disorders	Diarrhea <sup>1</sup> Abdominal pain <sup>1</sup> Nausea Abdominal discomfort Flatulence Constipation	Vomiting Dry mouth	Candidiasis	
Hepatobiliary disorders		Liver function test abnormal		Hepatitis drug-induced <sup>2</sup>
Skin and subcutaneous tissue disorders		Urticaria Pruritus Rash		
General disorders and administration site conditions		Asthenia Appetite changes		

<sup>1</sup> see section 'Description of selected adverse reactions'

<sup>2</sup> adverse reactions that have been observed during post approval of dexlansoprazole (as these reactions are reported voluntarily from a population of uncertain size, frequency cannot be estimated from the available data)

### Description of selected adverse reactions

#### *Diarrhea and abdominal pain*

In the Phase 3 clinical studies, the most commonly reported adverse reaction was diarrhoea (excluding infective diarrhoea), the majority of which were non-serious. Overall, few subjects (2.4%) prematurely discontinued due to an adverse reaction while receiving dexlansoprazole therapy. The most common ( $\geq 0.5\%$ ) adverse reactions leading to premature discontinuation were diarrhoea, gastrointestinal and abdominal pains. Initial onset of diarrhoea and abdominal pain was independent of the duration of exposure, and the majority of these events were mild to moderate in severity. There were no apparent dose-related trends observed across dexlansoprazole doses for the incidence of these events.

#### *Hypersensitivity*

There have been post-marketing cases reporting serious hypersensitivity reactions. Hypersensitivity reactions were more frequently reported in females (74%). The majority of the serious cases were managed with steroids and/or antihistamines and withdrawal of the medicinal product. Severe reactions of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) were reported in few patients.

#### *Haemolytic anaemia*

There have been few serious post-marketing reports of haemolytic anaemia after approximately four to seven months on dexlansoprazole 60 mg therapy.

### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: [www.hpra.ie](http://www.hpra.ie); E-mail: [medsafety@hpra.ie](mailto:medsafety@hpra.ie).

## **4.9 Overdose**

The effects of overdose of dexlansoprazole in humans are not known (although the acute toxicity is likely to be low) and, consequently, instruction for treatment cannot be given.

There have been no reports of significant overdose of Dexlansoprazole Takeda. Multiple doses of Dexlansoprazole Takeda 120 mg and a single dose of Dexlansoprazole Takeda 300 mg did not result in death or other severe adverse events. Serious adverse reactions of hypertension have been reported in association with twice daily doses of Dexlansoprazole Takeda 60 mg. Non-serious adverse reactions observed with twice daily doses of Dexlansoprazole Takeda 60 mg include hot flushes, contusion, oropharyngeal pain, and weight loss.

In the case of suspected overdose the patient should be monitored. Dexlansoprazole is not significantly eliminated by haemodialysis. If necessary, gastric emptying, charcoal and symptomatic therapy is recommended.

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC06

#### Mechanism of action

Dexlansoprazole is the R-enantiomer of lansoprazole. It is a gastric PPI. It inhibits the final stage of gastric acid formation by inhibiting the activity of H<sup>+</sup>/K<sup>+</sup> ATPase of the parietal cells in the stomach. The inhibition is dose-

dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Dexlansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphhydryl group of H<sup>+</sup>/K<sup>+</sup>ATPase causing inhibition of the enzyme activity.

### Pharmacodynamic effects

#### *Antisecretory activity*

The antisecretory activity of Dexlansoprazole Takeda has been studied in healthy subjects taking dexlansoprazole 60 mg or lansoprazole 30 mg once daily for five days. The average intragastric pH was 4.55 for Dexlansoprazole Takeda and 4.13 for lansoprazole. The average percentage of time throughout the day in which the intragastric pH is maintained above 4 was 71% (17 hours) with Dexlansoprazole Takeda and 60% (14 hours) with lansoprazole.

#### *Serum gastrin effect*

The effect of Dexlansoprazole Takeda on serum gastrin concentrations was evaluated in patients in clinical trials up to 12 months. The mean fasting gastrin concentrations increased from baseline during treatment with Dexlansoprazole Takeda 30 mg and 60 mg doses. In patients treated for more than 6 months, mean serum gastrin levels increased during approximately the first 3 months of treatment and were stable for the remainder of treatment. Mean serum gastrin levels returned to pre-treatment levels within one month of discontinuation of treatment.

#### *Enterochromaffin-Like Cell (ECL) Effects*

There were no reports of ECL cell hyperplasia in gastric biopsy specimens obtained from patients treated with Dexlansoprazole Takeda 30 mg, 60 mg or 90 mg for up to 12 months.

#### *Effect on Cardiac Repolarisation*

A study was conducted to assess the potential of Dexlansoprazole Takeda to prolong the QT/QTc interval in healthy adult subjects. Dexlansoprazole Takeda doses of 90 mg or 300 mg did not delay cardiac repolarisation compared to placebo. The positive control (moxifloxacin) produced statistically significantly greater mean maximum and time-averaged QT/QTc intervals compared to placebo.

### Clinical efficacy and safety

#### *Treatment of erosive reflux oesophagitis*

Two multi-center, double-blind, active-controlled, randomised, 8-week studies were conducted in patients with endoscopically confirmed erosive reflux oesophagitis. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). Patients were randomised to one of the following three treatment groups: Dexlansoprazole Takeda 60 mg daily, Dexlansoprazole Takeda 90 mg daily or lansoprazole 30 mg daily. A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54% male. Based on the Los Angeles Classification, 71% of patients had Grades A and B erosive reflux oesophagitis (mild) and 29% of patients had Grades C and D erosive reflux oesophagitis (moderate to severe) before treatment.

By the life-table method of analysis Dexlansoprazole Takeda 60 mg healed 92.3% to 93.1% of patients versus 86.1% to 91.5% for lansoprazole 30 mg after 8 weeks of treatment (primary). Non-inferiority was demonstrated in both studies. Statistical superiority was not established using log-rank tests.

After 4 weeks of treatment (secondary), the healing rates by the life-table method were 77.0% to 80.1% versus 76.5% to 77.0% for lansoprazole 30 mg.

The life-table healing rates at Week 8 for patients with moderate to severe erosive reflux oesophagitis (secondary) were 88.9% and 74.5% for Dexlansoprazole Takeda 60 mg and lansoprazole 30 mg, respectively, in the first study. The difference was statistically significant (p=0.011). In the second study, the Week 8 life-table healing rates were 87.6% and 87.7% for Dexlansoprazole Takeda 60 mg and lansoprazole 30 mg, respectively, and were not statistically

significantly different.

Dexlansoprazole Takeda 90 mg was studied and did not provide additional clinical benefit over Dexlansoprazole Takeda 60 mg.

#### *Maintenance of healed erosive reflux oesophagitis*

A multi-center, double-blind, placebo-controlled, randomised study was conducted in patients who successfully completed an erosive reflux oesophagitis study and showed endoscopically confirmed healed erosive reflux oesophagitis. Maintenance of healing and symptom relief over a six-month period were evaluated with Dexlansoprazole Takeda 30 mg or 60 mg once daily compared to placebo. A total of 445 patients were enrolled and ranged in age from 18 to 85 years (median age 49 years), with 52% female.

By the life-table method, Dexlansoprazole Takeda 30 mg and 60 mg demonstrated statistically significantly higher rates of maintenance of healed erosive reflux oesophagitis (74.9% and 82.5%, respectively) than placebo (27.2%) at Month 6 ( $p < 0.00001$ ).

For patients with more severe grades of erosive reflux oesophagitis (Grades C or D) before healing, Dexlansoprazole Takeda 30 mg and 60 mg also achieved statistically significantly higher 6-month maintenance rates than placebo by the life-table method.

Dexlansoprazole Takeda 30 mg and 60 mg achieved statistically significantly ( $p < 0.00001$ ) greater percentages of heartburn relief during the study treatment period. The median percentages of 24-hour heartburn-free days were 96.1%, 90.9% and 28.6% for Dexlansoprazole Takeda 30 mg, 60 mg and placebo, respectively. The median percentages of nights without heartburn were 98.9%, 96.2% and 71.7% for Dexlansoprazole Takeda 30 mg, 60 mg and placebo, respectively.

In a second study (N=451) of Dexlansoprazole Takeda 60 mg and 90 mg versus placebo, Dexlansoprazole Takeda 60 mg showed similar results to the first study in the maintenance of healed erosive reflux oesophagitis and heartburn relief. Dexlansoprazole Takeda 90 mg did not provide additional clinical benefit over Dexlansoprazole Takeda 60 mg.

#### *Symptomatic non-erosive GORD*

A multi-center, double-blind, placebo-controlled, randomised, 4-week study was conducted in patients with a diagnosis of symptomatic GORD made primarily by presentation of symptoms. These patients who identified heartburn as their primary symptom, had a history of heartburn for 6 months or longer, had heartburn on at least 4 of 7 days immediately prior to randomisation and had no esophageal erosions as confirmed by endoscopy. However, patients with symptoms which were not acid-related may not have been excluded using these inclusion criteria. Patients were randomised to one of the following treatment groups: Dexlansoprazole Takeda 30 mg daily, 60 mg daily, or placebo. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71% female.

Dexlansoprazole Takeda 30 mg provided statistically significantly greater percent of days with heartburn-free 24-hour periods and percent of nights without heartburn (respectively 54.9% and 80.8%) over placebo (respectively 18.5% and 51.7%) as assessed by daily diary over 4 weeks. A higher percentage of patients on Dexlansoprazole Takeda 30 mg had heartburn-free 24-hour periods compared to placebo through 4 weeks of treatment. Dexlansoprazole Takeda 60 mg was studied and provided no additional clinical benefit over Dexlansoprazole Takeda 30 mg.

A second multi-center, double blind, placebo-controlled, randomised, 4-week study was conducted in patients with a history of nocturnal heartburn and GORD associated sleep disturbances on at least 3 of 7 nights immediately prior to randomisation. Patients were randomised to receive Dexlansoprazole Takeda 30 mg or placebo daily. A total of 305 patients were enrolled and ranged in age from 18 to 66 years (median age 45 years) with 63.9% female. Dexlansoprazole Takeda 30 mg provided statistically significantly greater percent of nights without heartburn (73.1%) over placebo (35.7%) as assessed by daily diary over 4 weeks.

A third multi-center, single blind study enrolled 178 patients with a history of symptomatic GORD. Patients whose symptoms were well-controlled during a run-in period while taking a PPI other than Dexlansoprazole Takeda twice a day subsequently received blinded Dexlansoprazole Takeda 30 mg (morning) and placebo (evening) for 6 weeks. Well-controlled was defined as having a weekly average of  $\leq 1$  episode of heartburn during the last 4 weeks of both the 6 week run-in and treatment periods. A total of 142 patients were included in the analysis. Ages ranged from 22 to 90 years (median age 53 years) with 56% female. After switching from twice daily PPI therapy to once daily Dexlansoprazole Takeda 30 mg, 88% of patients' heartburn remained well-controlled.

## 5.2 Pharmacokinetic properties

The formulation of Dexlansoprazole Takeda utilising dual delayed release technology results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours.

### Absorption

After oral administration of Dexlansoprazole Takeda 30 mg or 60 mg to healthy subjects, mean  $C_{\max}$  and AUC values of dexlansoprazole increased approximately dose proportionally. Peak plasma levels occur within 4 to 6 hours.

### Distribution

Plasma protein binding of dexlansoprazole ranged from 96.1% to 98.8% in healthy subjects and was independent of concentration from 0.01 to 20 mcg per mL. The apparent volume of distribution after multiple doses in symptomatic GORD patients was 40.3 L.

### Biotransformation

Dexlansoprazole is extensively metabolised in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates; extensive metabolisers (\*1/\*1), intermediate metabolisers (\*1/mutant) and poor metabolisers (mutant/mutant). Systemic exposure of dexlansoprazole is generally higher in intermediate and poor metabolisers. Dexlansoprazole is the major circulating component in plasma, regardless of CYP2C19 metaboliser status. In CYP2C19 intermediate and extensive metabolisers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolisers dexlansoprazole sulfone is the major plasma metabolite.

### Elimination

Following the administration of Dexlansoprazole Takeda, no unchanged dexlansoprazole is excreted in urine. Following the administration of [ $^{14}\text{C}$ ]dexlansoprazole to healthy male subjects, approximately 50.7% of the administered radioactivity was excreted in urine and 47.6% in the feces. Apparent clearance in healthy subjects was 11.4 to 11.6 L/h, respectively, after 5-days of 30 or 60 mg once daily administration.

### Linearity/Non-linearity

Following a single and multiple daily dexlansoprazole 30 to 120 mg doses to healthy subjects, mean dexlansoprazole  $C_{\max}$  and AUC values increased approximately dose proportionally over the entire dose range. The pharmacokinetics of dexlansoprazole was both dose- and time-independent, with an estimated terminal elimination half-life of approximately 1 to 2 hours. Therefore, little or no active substance accumulation was observed for dexlansoprazole after once daily doses of dexlansoprazole, as evidenced by similar  $C_{\max}$  and AUC values after a single and multiple once-daily doses at steady-state.

### Effect of Food

Dexlansoprazole Takeda can be taken without regard to food or the timing of food. In food-effect studies in healthy subjects receiving Dexlansoprazole Takeda, increases in  $C_{\max}$  ranged from 12% to 55% and increases in AUC ranged from 9% to 37% under various fed conditions compared to fasting. However, no relevant differences with regard to intragastric pH were observed. An additional study showed that administration of 60 mg Dexlansoprazole Takeda prior to consumption of breakfast, lunch, dinner or an evening snack did not have an effect on dexlansoprazole exposure, or a clinically relevant effect on 24-hour intragastric pH control.

### Special patient populations

#### *Elderly*

In a study of male and female healthy subjects who received a single oral dose of Dexlansoprazole Takeda 60 mg, the terminal elimination half-life of dexlansoprazole was statistically significantly longer in elderly subjects compared to younger subjects (2.23 and 1.5 hours, respectively). In addition, dexlansoprazole exhibited higher systemic exposure (AUC) in elderly subjects (34.5% higher) than younger subjects. These differences were not clinically relevant. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications.

#### *Renal impairment*

Dexlansoprazole is extensively metabolised in the liver to inactive metabolites, and no parent active substance is recovered in the urine following an oral dose of dexlansoprazole. Therefore, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with renal impairment, and no studies were conducted in subjects with renal impairment (see section 4.4).

#### *Hepatic impairment*

In a study of patients with moderately impaired hepatic function who received a single oral dose of Dexlansoprazole Takeda 60 mg, plasma exposure (AUC) of bound and unbound dexlansoprazole in the hepatic impairment group was approximately 2 times greater compared to subjects with normal hepatic function. This difference in exposure was not due to a difference in protein binding between the two liver function groups. No adjustment for Dexlansoprazole Takeda is necessary for patients with mild hepatic impairment. Dexlansoprazole Takeda 30 mg should be considered for patients with moderate hepatic impairment. No studies have been conducted in patients with severe hepatic impairment, the use of dexlansoprazole is not recommended for these patients (see section 4.4).

#### *Gender*

In a study of male and female healthy subjects who received a single oral dose of Dexlansoprazole Takeda 60 mg, females had higher (42.8%) systemic exposure (AUC) than males. No dosage adjustment is necessary in patients based on gender.

## 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, toxicity to reproduction and development.

Lansoprazole is a racemic mixture of R- and S-enantiomers. Following administration of lansoprazole in humans and animals, the major component circulating in plasma is dexlansoprazole, the R-enantiomer of lansoprazole. Therefore, the carcinogenic potential of dexlansoprazole was assessed using existing lansoprazole studies.

In rat carcinogenicity studies, lansoprazole produced dose-related gastric ECL cell hyperplasia and ECL cell carcinoids associated with hypergastrinaemia due to inhibition of acid secretion. Intestinal metaplasia was also observed, as were Leydig cell hyperplasia and benign Leydig cell tumours in the testes. After 18 months of treatment retinal atrophy was observed. This was not observed in monkeys, dogs, or mice.

In mouse carcinogenicity studies dose-related gastric ECL cell hyperplasia developed as well as liver tumours and adenoma of rete testis.

The clinical relevance of these findings is unknown.

Lansoprazole was positive in the Ames test and the *in vitro* human lymphocyte chromosomal aberration assay. Lansoprazole was not genotoxic in the *ex vivo* rat hepatocyte unscheduled DNA synthesis (UDS) test, the *in vivo* mouse micronucleus test, or the rat bone marrow cell chromosomal aberration test.

Dexlansoprazole was positive in the Ames test and in the *in vitro* chromosome aberration test using Chinese hamster lung cells. Dexlansoprazole was negative in the *in vivo* mouse micronucleus test.

A reproduction study conducted in rabbits at oral dexlansoprazole doses up to approximately 9 times the maximum recommended human dexlansoprazole dose (60 mg per day), based on body surface area (BSA), revealed no evidence of harm to the fetus due to dexlansoprazole. In addition, reproduction studies performed in pregnant rats with oral lansoprazole at doses up to 40 times the recommended human lansoprazole dose, based on BSA, and in pregnant rabbits at oral lansoprazole doses up to 16 times the recommended human lansoprazole dose, based on BSA, revealed no evidence of impaired fertility or harm to the fetus due to lansoprazole.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

#### Capsule content

Silica, colloidal anhydrous

Hydroxypropylcellulose

Hypromellose

Low-substituted hydroxypropyl cellulose

Magnesium carbonate, heavy

Methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30 per cent (Methacrylic acid units, Ethyl acrylate units, Sodium laurilsulfate, Polysorbate 80)

Methacrylic acid-methyl methacrylate copolymer (1:1)

Methacrylic acid-methyl methacrylate copolymer (1:2)

Macrogol 8000

Polysorbate 80

Sucrose

Sugar spheres (Sucrose, Corn starch)

Talc

Titanium dioxide (E171)

Triethyl citrate

Capsule shell 60 mg  
Carrageenan (E407)  
Titanium dioxide (E171)  
Hypromellose  
Potassium chloride  
Water, purified  
Indigotine (E132)

Printing ink  
Iron oxide, red (E172)  
Iron oxide, yellow (E172)  
Indigotine (E132)  
Carnauba wax  
Shellac  
Glycerol mono-oleate

## **6.2 Incompatibilities**

Not applicable.

## **6.3 Shelf life**

3 years

## **6.4 Special precautions for storage**

Do not store above 25°C.

## **6.5 Nature and contents of container**

PVC/PE/polychlorotrifluoroethylene (PCTFE) - aluminium blister packs containing 14 or 28 capsules.

Not all pack sizes may be marketed.

## **6.6 Special precautions for disposal and other handling**

No special requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Takeda Pharma A/S  
Dybendal Alle 10  
2630 Taastrup  
Denmark

## **8 MARKETING AUTHORISATION NUMBER**

PA1864/002/002

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 25<sup>th</sup> November 2013

## **10 DATE OF REVISION OF THE TEXT**

July 2015